Advances in Disease-Modifying Therapy of Neuromyelitis Optic Spectrum Disorders

VernacularTitle:视神经脊髓炎谱系疾病的疾病修饰治疗进展
Author: Xuanling ZHANG ¹ ; Chaoyang CHEN ; Ran WEI ; Ying ZHOU
Author Information

1. 北京大学第一医院药剂科,北京 100034
Keywords: neuromyelitis optic spectrum disorders; disease-modifying therapy; medication
From: JOURNAL OF RARE DISEASES 2024;3(2):246-251
CountryChina
Language:Chinese
Abstract: Neuromyelitis optic spectrum disorders(NMOSD)is a serious inflammatory demyelinating disease.Clinical treatment of NMOSD mainly involves acute phase treatment and remission phase prevention treatment.Disease-modifying therapy(DMT)in remission phase of NMOSD can effectively reduce disease re-currence and delay disability progression.At present,the drugs commonly used for DMT at home and abroad in-clude classical immunosuppression,B-cell surface antigen monoclonal antibody,complement targeting mono-clonal antibody,IL-6 receptor-targeting monoclonal antibody,etc.This paper mainly reviews the DMT drugs ef-ficacy,safety,as well as the marketing status of NMOSD.